Innovative haptenation approaches are also being explored; for example, the covalent KRAS G12C inhibitor ARS1620 can generate haptenated peptide–MHC complexes that function as novel tumor-specific neoantigens, enabling the use of bispecific T-cell engagers to elicit cytotoxicity even in resistant clones [37]. This evidence concerns the gene KRAS and neoplasm.